Symptoms and General Pathology

All Conditions

Neoplasms

Gland and Hormone Related Diseases

Nervous System Diseases

Heart and Blood Diseases

Diseases and Abnormalities at or Before Birth

Skin and Connective Tissue Diseases

Rare Diseases

Syndrome

Neuroendocrine Tumors

Endocrine Gland Neoplasms

Von Hippel-Lindau Disease

Meningioma

Multiple Endocrine Neoplasia

Multiple Endocrine Neoplasia Type 1

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neoplasms, Vascular Tissue

Meningeal Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Neurocutaneous Syndromes

Angiomatosis

Vascular Diseases

Ciliopathies

Congenital Abnormalities

Abnormalities, Multiple

Genetic Diseases, Inborn

Endocrine System Diseases

Neoplasms, Multiple Primary

Neoplastic Syndromes, Hereditary

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

Gastrointestinal Agents

All Drugs and Chemicals

Amino Acids

Octreotide

Edotreotide

Antineoplastic Agents, Hormonal

Radiopharmaceuticals

Phenylalanine

Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.

Computed Tomography

Gallium Ga 68-Edotreotide

Positron Emission Tomography

Homer A Macapinlac, MD

This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.

PRIMARY OBJECTIVES:

I. To substitute 68Ga-DOTATOC for 111In-pentetreotide on an expanded access basis, in tumor imaging for study subjects, where the care provider believes that somatostatin imaging is clinically indicated, until such time as 68Ga-DOTATOC becomes commercially available.

SECONDARY OBJECTIVES:

I. To gain experience in the utility of 68Ga-DOTATOC in the management of neuroendocrine tumors at The University of Texas M.D. Anderson Cancer Center (MDACC).

II. To acquire proficiency in generating 68Ga-DOTATOC for human use at MDACC.

OUTLINE:

Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.

After completion of study, participants are followed up at 24 hours or within 72 hours, and at 30 days.

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC

As measured by National Cancer Institute Common Terminology Criteria for Adverse Events version 4. Traceable toxicity/safety data will be assessed. Adverse events and vital signs will be monitored and described with descriptive statistics.

National Cancer Institute (NCI)

M.D. Anderson Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors	NCT03001349	Meningioma Metastatic Well... Multiple Endocr... Neuroendocrine ... Somatostatin Po... Von Hippel-Lind...	Computed Tomogr... Gallium Ga 68-E... Positron Emissi...	-	M.D. Anderson Cancer Center
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors	NCT03001349	Meningioma Metastatic Well... Multiple Endocr... Neuroendocrine ... Somatostatin Po... Von Hippel-Lind...	Computed Tomogr... Gallium Ga 68-E... Positron Emissi...	-	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for metastatic well differentiated neuroendocrine neoplasm